Edwin Moses to help guide Dark Blue into the clinic

Dark Blue Therapeutics, a UK discovery and development biotech developing precision oncology medicines, has announced the appointment of Edwin Moses (pictured, above) as chairman.

Regarded as an industry heavyweight, Dr Moses has more than 30 years of board level experience as a serial entrepreneur and value creator in more than 20 European life science companies. 

As chief executive, he built, Oxford Asymmetry International and Ablynx, led successful IPOs on various stock market indexes, and raised more than $500 million in equity and debt financing.  He was responsible for the sales of both companies, generating values of £316 million ($409 million) and $4.8 billion, respectively.